Ken Griffin’s Verona Pharma VRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-461,869
Closed -$49.3M 14199
2025
Q3
$49.3M Sell
461,869
-934,775
-67% -$97.6M 0.01% 1387
2025
Q2
$132M Buy
1,396,644
+1,052,924
+306% +$78M 0.02% 589
2025
Q1
$21.8M Sell
343,720
-1,008,993
-75% -$60.4M ﹤0.01% 1945
2024
Q4
$62.8M Buy
1,352,713
+174,691
+15% +$6.56M 0.01% 1082
2024
Q3
$33.9M Buy
1,178,022
+1,075,407
+1,048% +$26.5M 0.01% 1557
2024
Q2
$1.48M Sell
102,615
-39,597
-28% -$578K ﹤0.01% 5857
2024
Q1
$2.29M Buy
142,212
+114,022
+404% +$1.97M ﹤0.01% 5260
2023
Q4
$560K Sell
28,190
-148,293
-84% -$2.19M ﹤0.01% 7847
2023
Q3
$2.88M Sell
176,483
-109,383
-38% -$2.11M ﹤0.01% 4554
2023
Q2
$6.04M Buy
285,866
+17,618
+7% +$376K ﹤0.01% 3350
2023
Q1
$5.39M Buy
+268,248
New +$5.79M ﹤0.01% 3688
2022
Q4
Sell
-695,260
Closed -$9.26M 15511
2022
Q3
$7.11M Buy
695,260
+684,511
+6,368% +$5.77M ﹤0.01% 3294
2022
Q2
$45K Buy
+10,749
New +$46K ﹤0.01% 12005
2022
Q1
Sell
-11,889
Closed -$69.2K 14667
2021
Q4
$80K Sell
11,889
-10,981
-48% -$56.1K ﹤0.01% 12943
2021
Q3
$125K Buy
+22,870
New +$133K ﹤0.01% 12596
2019
Q2
Sell
-10,824
Closed -$68K 9921
2019
Q1
$68K Buy
+10,824
New +$70.5K ﹤0.01% 8707

Other funds holding VRNA

Ken Griffin's VRNA Position: Q4 2025 in Review

Ken Griffin sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 461,869 shares — an estimated $49.3M sold.

Ken Griffin first reported a position in VRNA in Q1 2019 and held it in 16 quarters. The position peaked at $132M in Q2 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

  • Ken Griffin reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
  • Ken Griffin sold 461,869 Verona Pharma shares in Q4 2025, an estimated $49.3M.
  • Ken Griffin first reported a position in Verona Pharma in Q1 2019 and held it in 16 quarters.
  • Ken Griffin's Verona Pharma position peaked at $132M in Q2 2025.
  • 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.